Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jason Ice

Internal Medicine Parma, OH Doctor of Osteopathy

NPI 1467951863 CMS profile 5698226

7007 Powers Blvd, Parma, OH 44129

Open in the dashboard

General payments

$11,919

773 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Ice of Parma, OH is reported in the CMS Open Payments database as having received $11,919 across 773 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,848 108
2024 General $1,481 90
2023 General $2,857 190
2022 General $3,821 273
2021 General $1,892 111
2020 General $20 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Ice
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jason Ice were reported at $1,848. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jason Ice Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $20 $119 $33–$402 $114
2021 $1,892 $135 $37–$521 $132
2022 $3,821 $141 $42–$496 $149
2023 $2,857 $149 $45–$519 $160
2024 $1,481 $154 $47–$537 $164
2025 $1,848 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $2,450 157 payments
  2. Novo Nordisk Inc $1,256 79 payments
  3. Pfizer Inc. $804 58 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $754 66 payments
  5. AstraZeneca Pharmaceuticals LP $687 33 payments
  6. Lilly USA, LLC $656 53 payments
  7. GlaxoSmithKline, LLC. $651 47 payments
  8. Janssen Pharmaceuticals, Inc $611 36 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $563 43 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $412 28 payments
  11. Other $3,074 173 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $11,856 770 payments
  2. Education $63 3 payments
Products named General payments · program years 2020–2025
  1. UBRELVY $1,055 69 payments
  2. Ozempic $954 64 payments
  3. RYBELSUS $942 63 payments
  4. NURTEC ODT Primary Care $918 79 payments
  5. QULIPTA $581 42 payments
  6. TRELEGY ELLIPTA $574 40 payments
  7. XIFAXAN $563 43 payments
  8. NURTEC ODT Pain $505 41 payments
  9. XARELTO $414 27 payments
  10. LINZESS $397 24 payments
  11. Other $8,857 536 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 156 drugs

Part D claims

10,733

Median for Internal Medicine: 777

Drug cost

$720,437

Median for Internal Medicine: $73,373

Branded share of claims

21%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 115 $107,244
Ozempic Semaglutide Brand 84 $87,075
Eliquis Apixaban Brand 66 $66,995
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 77 $66,177
Xarelto Rivaroxaban Brand 49 $53,023
Trulicity Dulaglutide Brand 47 $42,496
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 27 $16,762
Tresiba Flextouch U-100 Insulin Degludec Brand 29 $16,448
Januvia Sitagliptin Phosphate Brand 11 $16,429
Repatha Sureclick Evolocumab Brand 21 $16,368

The 10 drugs with the highest cost, of 156 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$129,888

Of which drugs: $14,549

Medicare patients

499

Average age 76

Services billed

2,428

218 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 41%
Diabetes 35%
Heart failure 27%
Chronic kidney disease 26%
Atrial fibrillation 24%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 39 39 $11,327
Vaccine for influenza for injection into muscle 90662 Office 47 47 $3,086

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $104
$104 77 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $92
$92 — —
VRAYLAR
  • AbbVie, Inc. $79
$79 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $63
  • Lilly USA, LLC $16
$79 115 —
UBRELVY
  • AbbVie, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

773 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record